Biologic therapies have a huge impact on psoriasis treatment, helping patients achieve clearer or clear skin, although issues ...
At the recent American Academy of Dermatology annual meeting, experts emphasized that psoriasis is more than a skin disease -- with implications for long-term cardiovascular health. I just want to ...
Please provide your email address to receive an email when new articles are posted on . The proportion of deucravacitinib-treated patients that reported no quality-of-life impact increased from 0% at ...
The use of GLP-1 RAs may be appropriate among select patients with psoriasis, although additional research is needed to guide ...
A >500-patient, randomized, double-blind phase 3 trial showed CT-P43 achieved PASI 75 equivalence at week 12 versus ustekinumab under standard induction and q12w maintenance dosing. Durability through ...
MedPage Today on MSN
GLP-1 drug makes its case for treating plaque psoriasis
Adding tirzepatide helped patients shed pounds, improved complete skin clearance rates ...
Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the population and is mediated ...
The U.S. Food and Drug Administration has approved Johnson & Johnson's Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results